13F HOLDINGS REPORT
Lynx1 Capital Management LP
Quarter ended Q3 2025 · Filed November 13, 2025 · Accession 0001085146-25-005988
Total Value
$491.3M
Positions
14
Other Managers
1
Confidential Omitted
No
Holdings (14)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | MERUS N V | N5749R100 | 1,534,141 | $144.4M | 29.40% |
| 2 | STOKE THERAPEUTICS INC | STOK | 5,404,674 | $109.9M | 22.37% |
| 3 | GH RESEARCH PLC | GHRS | 8,601,189 | $104.3M | 21.23% |
| 4 | PROTAGONIST THERAPEUTICS INC | PTGX | 700,014 | $46.5M | 9.47% |
| 5 | CULLINAN THERAPEUTICS INC | CGEM | 5,766,090 | $34.2M | 6.96% |
| 6 | C4 THERAPEUTICS INC | CCCC | 7,098,133 | $15.8M | 3.21% |
| 7 | TSCAN THERAPEUTICS INC | TCRX | 7,857,347 | $14.3M | 2.91% |
| 8 | PRECISION BIOSCIENCES INC | DTIL | 1,042,596 | $5.8M | 1.17% |
| 9 | ADC THERAPEUTICS SA | ADCT | 1,325,848 | $5.3M | 1.08% |
| 10 | PASSAGE BIO INC | PASG | 623,704 | $5.0M | 1.02% |
| 11 | DENALI THERAPEUTICS INC | DNLI | 261,687 | $3.8M | 0.77% |
| 12 | IBIO INC | IBIO | 1,055,897 | $874,072 | 0.18% |
| 13 | ALLOGENE THERAPEUTICS INC | ALLO | 546,119 | $677,188 | 0.14% |
| 14 | DESIGN THERAPEUTICS INC | DSGN | 65,954 | $496,634 | 0.10% |